Huizinga Robert Bindert's Form 4 filing
Aurinia Pharmaceuticals Inc. (AUPH) · filed Sep 14, 2021
- Accession no.
- 0001628280-21-018595
- Filed
- Sep 14, 2021
- Trade date
- Sep 10-14, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $687.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Huizinga Robert BindertCIK 0001837648 | Officer (EVP of Research) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2021 | Common Stock | SSaleDisposed | −5,000 | $19.83 | −$99,150 | 133,592 | Direct | |
| Sep 10, 2021 | Common Stock | SSaleDisposed | −5,000 | $19.76 | −$98,800 | 128,592 | Direct | |
| Sep 14, 2021 | Common Stock | SSaleDisposed | −22,500 | $21.75 | −$489,375 | 106,092 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.